Debiopharm Innovation Fund and Philips Health Technology Ventures both contributed to the latest round for the cancer care software producer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Hebei Port, Pharscin Pharma, Xiamen Fig, Fujian Sunner and Sichuan Daily Press have all contributed to a $229m biomedicine fund raised by the private equity vehicle.

Stanford-StartX Fund contributed to a $12m round for catheter monitor developer CloudCath, whose clinical advisory chairman hails from Stanford University.

ResMed joined another medical device producer, Cochlear, in a $27.2m round that will help Nyxoah get regulatory clearance for its sleep apnoea system in the US.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds

The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

Existing backer M12 reinvested in Innovaccer, pushing the total raised by the healthcare data management platform past the $120m mark.

Parkwalk Advisors is lining up investment to fund series C rounds for 10 of its portfolio companies, including spinouts of the universities of Oxford and Cambridge.